RGNXHealthcare · BiotechnologyThe 11 Wall Street analysts covering REGENXBIO, Inc. hold a median 12-month price target of $19 — +163.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 47 of 100 as at 31 Oct 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores REGENXBIO, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Issuance (72): The share count has been shrinking and the company is not leaning on new borrowing.
Volatility (19): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on RGNX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +163.9% from it.
Of the 20 most recent actions, 2 moved their price target up and 3 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 5 Oct 2026 | Mizuho | Initiates | Outperform | $22 |
| 25 Aug 2026 | Baird | Maintains | Outperform | — |
| 25 Aug 2026 | Baird | Maintains | Outperform | $32 → $29 |
| 25 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | $23 → $21 |
| 25 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 10 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 10 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | $26 → $23 |
| 7 Aug 2026 | Barclays | Downgrade | Equal-Weight | — |
| 7 Aug 2026 | Barclays | Downgrade | Equal-Weight | $12 |
| 24 June 2026 | HC Wainwright & Co. | Reiterates | Buy | $26 |
| 24 June 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 22 June 2026 | Baird | Maintains | Outperform | — |
| 22 June 2026 | Baird | Maintains | Outperform | $27 → $32 |
| 22 June 2026 | Leerink Partners | Maintains | Outperform | — |
| 22 June 2026 | Leerink Partners | Maintains | Outperform | $17 → $18 |
| 5 June 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 15 May 2026 | B of A Securities | Maintains | Buy | — |
| 15 May 2026 | Barclays | Maintains | Overweight | — |
| 9 Mar 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 6 Mar 2026 | Morgan Stanley | Maintains | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
RGNX appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 30 Oct 2026, REGENXBIO, Inc. returned −43.8% against +12.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 86% of US stocks
Cheaper than 43% of US stocks
Cheaper than 17% of US stocks
Cheaper than 79% of US stocks
Higher than 97% of US stocks
Higher than 94% of US stocks
Higher than 99% of US stocks
Higher than 85% of US stocks
Higher than 5% of US stocks
Higher than 10% of US stocks
Higher than 19% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
REGENXBIO, Inc. has a market value of $475.3M and an enterprise value of $620.2M.
Revenue in the twelve months to 30 June 2026: $174.5M. The latest quarter grew 405.7% year on year.
Net income over the same four quarters: −$196.4M, a −112.6% net margin.
Diluted earnings per share, trailing twelve months: $−3.79.
Free cash flow in the twelve months to 30 June 2026: −$249.7M.
Trailing P/E: −1.9×; forward P/E: −2.4× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
REGENXBIO, Inc. employs 371 people — $470K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own REGENXBIO, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zacks says Regenxbio has a combination of two key factors that could support an earnings beat in its upcoming report, and highlights key expectations.
Why it matters — The item focuses on expectations for RGNX’s upcoming earnings report.
REGENXBIO announced it will host a conference call on Thursday, November 5, at 8:00 a.m. to discuss its third-quarter 2026 financial results and operational highlights.
Why it matters — The call will provide RGNX watchers with information about the company’s quarterly results and operations.
REGENXBIO outlined clinical, manufacturing, and commercialization plans for sura-vec, an investigational one-time subretinal gene therapy for wet AMD, at a company event with retina specialists and executives. The headline points to a pivotal readout expected in Q4.
Why it matters — The plans and anticipated pivotal readout are relevant to RGNX watchers tracking sura-vec’s development.
Seeking Alpha published a transcript titled “REGENXBIO Inc. (RGNX) Discusses Clinical Program Progress and Commercial Outlook in Wet AMD and Rare Diseases.” The excerpt provides no details from the discussion.
Why it matters — The transcript concerns RGNX’s clinical programs and commercial outlook, but the excerpt does not disclose specific developments.
REGENXBIO announced an investor event at 1:00 p.m. on October 20 focused on surabgene lomparvovec (Sura-vec) in wet AMD. The event will include a clinical program overview and perspectives from retina specialists ahead of a pivotal-data readout anticipated in the fourth quarter of 2026.
Why it matters — The event will provide an update on RGNX’s Sura-vec program before its anticipated pivotal-data readout.
The 11 Wall Street analysts covering REGENXBIO, Inc. have a median 12-month price target of $19, with estimates ranging from $12 to $50. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 11 analysts covering REGENXBIO, Inc., 10 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks REGENXBIO, Inc. 47 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 31 Oct 2026, REGENXBIO, Inc. ranks 47 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Issuance (72 of 100).
No one can know that. What the data says: the median 12-month target from 11 analysts implies +163.9% from the last close, and Ticker Nerd's factor model ranks REGENXBIO, Inc. 47 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering REGENXBIO, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RGNX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $50 over the next 12 months.
REGENXBIO, Inc. returned -43.8% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
REGENXBIO Inc. is a clinical-stage biotechnology company focused on gene therapy.
The most recent item we track (Zacks Investment Research, 29 Oct 2026): "Regenxbio (RGNX) Expected to Beat Earnings Estimates: Should You Buy?". Zacks says Regenxbio has a combination of two key factors that could support an earnings beat in its upcoming report, and highlights key expectations.
REGENXBIO Inc. is a clinical-stage biotechnology company focused on gene therapy. REGENXBIO Inc. develops and commercializes recombinant adeno-associated virus (AAV)–based treatments designed to deliver functional genes to cells and address genetic defects. Its current work centers on therapeutic programs in retinal, metabolic, and neurodegenerative diseases, supported by its proprietary NAV Technology Platform. The company also licenses its AAV gene-delivery technology to other biotechnology partners, combining internal drug development with platform licensing. REGENXBIO Inc. plays a specialized role in the biotechnology market by advancing gene therapy candidates and enabling broader use of AAV-based delivery systems across the life sciences industry.
CEO Mr. Curran M. Simpson M.S. · 371 employees · United States · https://www.regenxbio.com
